COVID-19 Project Team: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 25: | Line 25: | ||
*[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]] | *[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]] | ||
*[[User:TayyabaAli|Tayyaba Ali, M.D.]] | *[[User:TayyabaAli|Tayyaba Ali, M.D.]] | ||
'''Dermatologic Disorders of COVID-19 Team Members''' | '''Dermatologic Disorders of COVID-19 Team Members''' | ||
*'''[[User:Aditya Ganti|Aditya Ganti, M.B.B.S.]]''' | *'''[[User:Aditya Ganti|Aditya Ganti, M.B.B.S.]]''' | ||
*[[user:Dr.Nuha|Nuha AL-Howthi, MD]] | *[[user:Dr.Nuha|Nuha AL-Howthi, MD]] | ||
*[[User:Nnabude|Ogechukwu Hannah Nnabude, MD]] | *[[User:Nnabude|Ogechukwu Hannah Nnabude, MD]] | ||
{{ColBreak}} | |||
'''Frequently Asked Inpatient Questions Team Members''' | '''Frequently Asked Inpatient Questions Team Members''' | ||
* '''[[User:Gurman4sandhu|Gurmandeep Singh Sandhu, M.B.B.S.]]''' | * '''[[User:Gurman4sandhu|Gurmandeep Singh Sandhu, M.B.B.S.]]''' | ||
| Line 40: | Line 39: | ||
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | * [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | ||
* [[Ogechukwu Hannah Nnabude, MD]] | * [[Ogechukwu Hannah Nnabude, MD]] | ||
'''Frequently Asked Outpatient Questions Team Members''' | '''Frequently Asked Outpatient Questions Team Members''' | ||
* '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]''' | * '''[[User:Roukoz Abou Karam|Roukoz Abou Karam, M.D.]]''' | ||
| Line 53: | Line 51: | ||
*[[User:TayyabaAli|Tayyaba Ali, M.D.]] | *[[User:TayyabaAli|Tayyaba Ali, M.D.]] | ||
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | * [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | ||
{{ColBreak}} | |||
'''Hematologic disorders of COVID-19 Team Members''' | '''Hematologic disorders of COVID-19 Team Members''' | ||
*'''[[User:Ramyar Ghandriz|Ramyar Ghandriz, M.D.]]''' | *'''[[User:Ramyar Ghandriz|Ramyar Ghandriz, M.D.]]''' | ||
| Line 65: | Line 63: | ||
*[[User:NNikravangolsefid|Nasrin Nikravangolsefid, M.D, MPH]] | *[[User:NNikravangolsefid|Nasrin Nikravangolsefid, M.D, MPH]] | ||
*[[User:MydahSajid|Mydah Sajid, M.D.]] | *[[User:MydahSajid|Mydah Sajid, M.D.]] | ||
'''Neurologic Disorders and COVID-19 Team Members''' | '''Neurologic Disorders and COVID-19 Team Members''' | ||
*'''[[User:Fahimeh Shojaei |Fahimeh Alsadat Shojaei, M.D.]]''' | *'''[[User:Fahimeh Shojaei |Fahimeh Alsadat Shojaei, M.D.]]''' | ||
| Line 75: | Line 72: | ||
*[[User:Parul Pahal|Parul Pahal, M.B.B.S.]] | *[[User:Parul Pahal|Parul Pahal, M.B.B.S.]] | ||
*[[User:Javaria Anwer|Javaria Anwer, M.B.B.S.]] | *[[User:Javaria Anwer|Javaria Anwer, M.B.B.S.]] | ||
{{ColBreak}} | |||
'''Ongoing Clinical Trials of COVID-19 Team Members''' | '''Ongoing Clinical Trials of COVID-19 Team Members''' | ||
* '''[[User:Hudakarman|Huda A. Karman M.D., M.P.H., M.S.]]''' | * '''[[User:Hudakarman|Huda A. Karman M.D., M.P.H., M.S.]]''' | ||
| Line 92: | Line 90: | ||
'''Infectious diseases and COVID-19''' | '''Infectious diseases and COVID-19''' | ||
* [[User:Zaida Obeidat|Zaida Obeidat, M.D.]] | * [[User:Zaida Obeidat|Zaida Obeidat, M.D.]] | ||
* [[User:Syed rizvi|Syed Rizvi, M.B.B.S.]] | |||
{{ColBreak}} | |||
'''[[COVID-19 medical therapy]] | '''[[COVID-19 medical therapy]] | ||
* [[User:Sara Zand|Sara Zand, M.D.]] | * [[User:Sara Zand|Sara Zand, M.D.]] | ||
'''[[COVID-19 other diagnostic studies]] | '''[[COVID-19 other diagnostic studies]] | ||
* [[User:Mandana Safakhah|Mandana Safakhah, M.D.]] | * [[User:Mandana Safakhah|Mandana Safakhah, M.D.]] | ||
Revision as of 21:51, 12 August 2020
| COVID-19 Project |
|---|
| Introduction |
| Team |
| Meetings' Summary |
| Topics |
| Ongoing Clinical Trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]